Early results from implementation of HIV pre-exposure prophylaxis (PrEP) with long-acting injectable cabotegravir for people with barriers to oral strategies, Italy, December 2024 to August 2025

作者：Davide Moschese, Rozenn Esvan, Chiara Fusetti, V Barchi, Maria Vittoria Cossu, Alessandro Giacinta, Samuel Lazzarin, Giulia Terracini, Francesco Caruso, Giulia Micheli, D Maddalena, Giulia Del Duca, Francesco Petri, G. Del Frate, Maddalena Matone, Damiano Farinacci, Andrea Giacomelli, Paolo Faccendini, Debora Visigalli, Sara Passacantilli, Agostino Riva, Andrea Antinori, Andrea Gori, Valentina Mazzotta · 发表于：Eurosurveillance · 年份：2025 · DOI：10.2807/1560-7917.es.2025.30.39.2500739 · 被引用次数：8 · 研究领域：HIV/AIDS Research and Interventions、HIV/AIDS oral health manifestations、HIV, Drug Use, Sexual Risk

Between December 2024 and August 2025, two Italian HIV/STI clinics offered long-acting injectable cabotegravir (CAB-LA) for HIV prevention in 265 individuals, representing the first European real-world implementation. Participants were prioritised based on vulnerabilities compromising oral pre-exposure prophylaxis (PrEP), such as poor adherence, comorbidities and behavioural barriers. Adherence to injections exceeded 95%, tolerability was favourable and only 1.5% discontinued for drug-related reasons. These findings demonstrate the feasibility of CAB-LA in European clinical services and support its use in specific populations.